- Technology/Device
- Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
-
Wenqi Fan, Chao Deng, Ruoyao Xu, Zhenqi Liu, Richard David Leslie, Zhiguang Zhou, Xia Li
-
Diabetes Metab J. 2025;49(2):235-251. Published online November 13, 2024
-
DOI: https://doi.org/10.4093/dmj.2024.0130
-
-
3,561
View
-
265
Download
-
1
Web of Science
-
4
Crossref
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
Automated insulin delivery (AID) systems studies are upsurging, half of which were published in the last 5 years. We aimed to evaluate the efficacy and safety of AID systems in patients with type 1 diabetes mellitus (T1DM).
Methods
We searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov until August 31, 2023. Randomized clinical trials that compared AID systems with other insulin-based treatments in patients with T1DM were considered eligible. Studies characteristics and glycemic metrics was extracted by three researchers independently.
Results
Sixty-five trials (3,623 patients) were included. The percentage of time in range (TIR) was 11.74% (95% confidence interval [CI], 9.37 to 14.12; P<0.001) higher with AID systems compared with control treatments. Patients on AID systems had more pronounced improvement of time below range when diabetes duration was more than 20 years (–1.80% vs. –0.86%, P=0.031) and baseline glycosylated hemoglobin lower than 7.5% (–1.93% vs. –0.87%, P=0.033). Dual-hormone full closed-loop systems revealed a greater improvement in TIR compared with hybrid closed-loop systems (–19.64% vs. –10.87%). Notably, glycemia risk index (GRI) (–3.74; 95% CI, –6.34 to –1.14; P<0.01) was also improved with AID therapy.
Conclusion
AID systems showed significant advantages compared to other insulin-based treatments in improving glucose control represented by TIR and GRI in patients with T1DM, with more favorable effect in euglycemia by dual-hormone full closedloop systems as well as less hypoglycemia for patients who are within target for glycemic control and have longer diabetes duration.
-
Citations
Citations to this article as recorded by  - Transitioning between automated insulin delivery systems: A focus on personalisation
Pilar Isabel Beato-Víbora, Ana Chico, Jesus Moreno-Fernandez, Sharona Azriel-Mira, Lia Nattero-Chávez, Rosario Vallejo Mora, Núria Alonso-Carril, Olga Simó-Servat, Eva Aguilera-Hurtado, Luz María Reyes Céspedes, Marisol Ruiz de Adana, Marta Domínguez, Ros
Diabetes Research and Clinical Practice.2025; 222: 112070. CrossRef - Advances in Continuous Glucose Monitoring: Clinical Applications
So Yoon Kwon, Jun Sung Moon
Endocrinology and Metabolism.2025; 40(2): 161. CrossRef - Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis (Diabetes Metab J 2025;49:235-51)
Wenqi Fan, Chao Deng, Zhiguang Zhou, Xia Li
Diabetes & Metabolism Journal.2025; 49(3): 520. CrossRef - Critical Insights into the Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2025;49:235-51)
Sami Ullah, Ayesha Ahmad, Kamil Ahmad Kamil, Minahil Laraib Asif, Abdullah Jan
Diabetes & Metabolism Journal.2025; 49(3): 516. CrossRef
|
KDA
